JP2024543966A5 - - Google Patents
Info
- Publication number
- JP2024543966A5 JP2024543966A5 JP2024532454A JP2024532454A JP2024543966A5 JP 2024543966 A5 JP2024543966 A5 JP 2024543966A5 JP 2024532454 A JP2024532454 A JP 2024532454A JP 2024532454 A JP2024532454 A JP 2024532454A JP 2024543966 A5 JP2024543966 A5 JP 2024543966A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- guide rna
- rna molecule
- base editing
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306681 | 2021-12-01 | ||
| EP21306681.4 | 2021-12-01 | ||
| PCT/EP2022/083904 WO2023099591A1 (en) | 2021-12-01 | 2022-11-30 | Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543966A JP2024543966A (ja) | 2024-11-26 |
| JP2024543966A5 true JP2024543966A5 (https=) | 2025-11-17 |
Family
ID=79185911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532454A Pending JP2024543966A (ja) | 2021-12-01 | 2022-11-30 | 赤血球特異的ＢＣＬ１１Ａエンハンサーの＋５５ｋｂ領域を編集することにより胎児ヘモグロビン含量を増加させるための方法。 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4441089A1 (https=) |
| JP (1) | JP2024543966A (https=) |
| WO (1) | WO2023099591A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2476689T3 (en) | 2007-05-10 | 2016-01-18 | Agilent Technologies Inc | Thiocarbonbeskyttende groups for RNA synthesis |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| CN112301024A (zh) | 2013-03-15 | 2021-02-02 | 通用医疗公司 | 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性 |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| JP7693552B2 (ja) | 2019-02-13 | 2025-06-17 | ビーム セラピューティクス インク． | アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法 |
| AU2020344547A1 (en) | 2019-09-09 | 2022-03-24 | Beam Therapeutics Inc. | Novel nucleobase editors and methods of using same |
| EP4017980A4 (en) * | 2019-09-30 | 2024-08-07 | The Children's Medical Center Corporation | BCL11A GUIDE AND BASIC EDITOR DISTRIBUTION |
-
2022
- 2022-11-30 WO PCT/EP2022/083904 patent/WO2023099591A1/en not_active Ceased
- 2022-11-30 EP EP22826075.8A patent/EP4441089A1/en active Pending
- 2022-11-30 JP JP2024532454A patent/JP2024543966A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Expanding the CRISPR toolbox in zebrafish for studying development and disease | |
| Pecori et al. | Functions and consequences of AID/APOBEC-mediated DNA and RNA deamination | |
| Tao et al. | Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing | |
| Trepotec et al. | Maximizing the translational yield of mRNA therapeutics by minimizing 5′-UTRs | |
| Gao et al. | Genomic and transcriptomic analyses of prime editing guide RNA–independent off-target effects by prime editors | |
| Zhou et al. | Programmable base editing of the sheep genome revealed no genome-wide off-target mutations | |
| JP2025026840A5 (https=) | ||
| JP2023526007A5 (https=) | ||
| JP2021523736A5 (https=) | ||
| JP2020510439A5 (https=) | ||
| Ye et al. | Therapy induced genome chaos: A novel mechanism of rapid cancer drug resistance | |
| JP2025183226A5 (https=) | ||
| Gott | Expanding genome capacity via RNA editing | |
| JP2024534720A5 (https=) | ||
| Liu et al. | Expanded targeting scope and enhanced base editing efficiency in rabbit using optimized xCas9 (3.7) | |
| JP2024543966A5 (https=) | ||
| Austin et al. | Molecular medicine of pulmonary arterial hypertension: from population genetics to precision medicine and gene editing | |
| Randazzo et al. | gEL DNA: A cloning-and polymerase chain reaction–free method for CRISPR-based multiplexed genome editing | |
| Jiao et al. | Random-PE: an efficient integration of random sequences into mammalian genome by prime editing | |
| Cao et al. | BASE EDITING: A PROMISING TOOL FOR GENETIC MANIPULATION IN MAMMALIAN SOMATIC AND STEM CELL LINES | |
| CN114875033A (zh) | sgRNA、CRISPR/Cas试剂及其应用 | |
| Susani et al. | Correction of a recessive genetic defect by CRISPR-Cas9-mediated endogenous repair | |
| Xu et al. | Optimization of the base editor BE4max in chicken somatic cells | |
| Mawson et al. | Precision genome editing with DNA base editors | |
| Liu et al. | Editing Properties of Base Editors with SpCas9-NG in Discarded Human Tripronuclear Zygotes |